Get the Stockscreener App
18.09
0.19%
0.035
Quantum Biopharma Ltd stock is traded at $18.09, with a volume of 73,958.
It is up +0.19% in the last 24 hours and down -17.27% over the past month.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
See More
Previous Close:
$18.05
Open:
$18.07
24h Volume:
73,958
Relative Volume:
0.28
Market Cap:
$69.01M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-19.44%
1M Performance:
-17.27%
6M Performance:
+190.29%
1Y Performance:
+334.74%
1-Day Range:
$17.50
$18.84
1-Week Range:
$17.50
$22.47
52-Week Range:
$2.70
$38.25
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
18.09 | 78.66M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Quantum Biopharma Ltd Stock (QNTM) Latest News
Momentum Indicator Shows Bearish Divergence in Quantum BioPharma Ltd.2025 Trading Volume Trends & Long-Term Investment Growth Plans - newsyoung.net
Quantum Biopharma shares rise 2.45% premarket after GC Biopharma signed an MOU with Thai Red Cross Society. - AInvest
Advanced analytics toolkit walkthrough for Quantum BioPharma Ltd.Weekly Trade Summary & Community Consensus Picks - Newser
Institutional scanner results for Quantum BioPharma Ltd.Weekly Trend Summary & Long-Term Capital Growth Ideas - Newser
Earnings visualization tools for Quantum BioPharma Ltd.July 2025 Institutional & Safe Capital Investment Plans - Newser
How to escape a deep drawdown in Quantum BioPharma Ltd.Weekly Trend Summary & Safe Entry Trade Signal Reports - Newser
How volatile is Quantum BioPharma Ltd. stockTrade Risk Assessment & Fast Exit and Entry Strategy Plans - thegnnews.com
Is Quantum BioPharma Ltd. stock entering bullish territoryJobs Report & High Win Rate Trade Alerts - Newser
Quantum Biopharma Ltd. shares fall 2.99% intraday amid federal budget cuts and VC funding into oncology ventures. - AInvest
Quantum Biopharma shares rise 3.09% premarket after corporate restructuring and VC funding in oncology ventures. - AInvest
Can a trend reversal in Quantum BioPharma Ltd. lead to recoveryQuarterly Market Review & Daily Price Action Insights - Newser
Quantum Biopharma Ltd. shares fall 1.08% intraday as China pharma firms turn to local reagent suppliers. - AInvest
Ranking Quantum BioPharma Ltd. among high performing stocks via toolsRisk Management & High Conviction Trade Alerts - Newser
What makes Quantum BioPharma Ltd. stock price move sharplyFree Real-Time Stock Signals - classian.co.kr
Quantum Biopharma shares rise 4.19% premarket after signing an agreement to manufacture oral drug formulation of Lucid-MS. - AInvest
Quantum BioPharma Ltd. Advances MS Treatment with CDMO Agreement for Lucid-MS - citybuzz -
Quantum BioPharma to seek shareholder approval for private placement - Investing.com
Quantum BioPharma Announces Update to Previously Announced Private Placement - Newsfile
Quantum BioPharma Signs Agreement to Manufacture Oral Drug - GlobeNewswire
Quantum BioPharma (QNTM) Shares Soar as Lead Drug Candidate Lucid-MS Nears Phase 2 Trial - AInvest
Why Quantum BioPharma (QNTM) Stock Is Soaring Today - 富途牛牛
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial - Lelezard
Why Is Quantum BioPharma In The News Today? Here’s An Important Update On Its Multiple Sclerosis Investigational Drug By Stocktwits - Investing.com India
Quantum Biopharma's Lucid-MS: A Neuroprotective Revolution in MS Treatment? - AInvest
Quantum Biopharma Seals Deal to Manufacture Oral Lucid-MS Ahead of Phase 2 Trial - MarketScreener
Quantum BioPharma Advances Lucid-MS for Phase 2 MS Trial - TipRanks
Quantum BioPharma signs manufacturing deal for MS drug oral form By Investing.com - Investing.com Nigeria
Quantum BioPharma signs manufacturing deal for MS drug oral form - Investing.com
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial | QNTM Stock - GuruFocus
Quantum BioPharma Signs Agreement with CDMO for Lucid-MS Oral Drug Formulation - AInvest
Breakthrough MS Drug Shows Promise in Mobility Recovery, Heads to Phase 2 Trial with New Oral Format - Stock Titan
Quantum BioPharma Reports Strong Q2 2025 with Key Developments - TipRanks
Is Quantum BioPharma (CSE:QNTM) Using Too Much Debt? - simplywall.st
Ripple Lawsuit Settlement Sparks Interest in XRP Treasury Strategy - CoinCentral
How sentiment analysis helps forecast Quantum BioPharma Ltd.Free Market Entry and Exit Point Tips - Newser
Quantum Biopharma shares rise 1.81% after-hours following promising MS drug study results. - AInvest
Quantum BioPharma Reports Promising PET Tracer Results for MS - TipRanks
Major MS Detection Breakthrough: Massachusetts General Hospital Unveils Revolutionary Brain Imaging Technology - Stock Titan
Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients - MarketScreener
Quantum BioPharma Q2 revenue down 15%, debt eliminated, cash sufficient beyond March 2027. - AInvest
Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets - GlobeNewswire
Quantum BioPharma reports strong Q2 with increased assets, no debt - Investing.com
Quantum Biopharma Reports Increased Liabilities in Latest Financial Statement - TipRanks
Quantum BioPharma Reports Triple Stock Growth, Breakthrough MS Drug Progress in Strong Q2 Earnings - Stock Titan
Quantum Biopharma Reports Strong Second Quarter with - GlobeNewswire
Quantum Biopharma Ltd. shares rise 1.19% after-hours following Cardiol Therapeutics' positive ARCHER trial results. - AInvest
Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug - AOL.com
Quantum BioPharma Reports Positive Phase 1 Results for MS Drug Lucid-MS - TipRanks
QNTMQuantum BioPharma Ltd Latest Stock News & Market Updates - Stock Titan
Quantum Group subsidiary received CSR for Phase 1 MAD trial - TipRanks
Quantum BioPharma stock falls after clinical trial report release - Investing.com
Quantum Biopharma Ltd Stock (QNTM) Financials Data
There is no financial data for Quantum Biopharma Ltd (QNTM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):